Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Press Release Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER TrialMarch 1, 2022
Press Release Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory BoardJanuary 19, 2022
Press Release Cardiol Therapeutics Announces Closing of US$50 Million Public OfferingNovember 5, 2021
Press Release Cardiol Therapeutics Announces Pricing of Public Offering of UnitsNovember 3, 2021
Press Release Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of UnitsNovember 2, 2021
Press Release Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx™ for Acute MyocarditisOctober 25, 2021
Press Release Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx™, into Brazil, Mexico, and CanadaOctober 18, 2021
Press Release Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceSeptember 16, 2021
Press Release Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants issued on June 4, 2020September 10, 2021
View more

2023 Cardiol Therapeutics. All right reserved.